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Background: Indacaterol is a novel, inhaled, ultra-long-acting b2-agonist bronchodilator for
maintenance use in patients with COPD. The aim of this paper is to assess the effect of inda-
caterol on dyspnoea and health status, using pooled study data to evaluate the relative effi-
cacy of indacaterol and existing bronchodilators.
Methods: Individual patient datawere pooled from three randomized, placebo-controlled studies
(NCT00393458; NCT00567996; NCT00463567), conducted in patients with moderate-to-severe
COPD. Treatments were double-blind indacaterol 150 mg (nZ 746) or 300 mg (nZ 853) once-daily,
formoterol 12 mg twice-daily (nZ 556), salmeterol 50 mg twice-daily (nZ 333) and placebo
(nZ1185);andopen-label tiotropium18mgonce-daily (nZ415). Evaluationafter 6months’ treat-
ment was by transition dyspnoea index (TDI; minimum clinically important difference [MCID] 1
point), and St George’s Respiratory Questionnaire (SGRQ; MCID 4 units).
Results: Differences from placebo in TDI total score were 1.01 (indacaterol 150 mg) 1.28 (indaca-
terol 300 mg), 0.74 (formoterol), 0.92 (salmeterol) and 0.88 (tiotropium) (all p< 0.05), with corre-
sponding odds ratios versus placebo for exceeding the MCID from baseline of 1.91, 2.69, 2.02, 1.79
and 1.49 (all p < 0.05). Differences versus placebo in SGRQ total score were 4.4 (indacaterol
150 mg), 3.4 (indacaterol 300 mg), 2.8 (formoterol), 4.0 (salmeterol) and 1.7 (tiotropium)
(all p < 0.05), with corresponding odds ratios versus placebo for exceeding the MCID of 1.95,
1.63, 1.54, 1.82 and 1.29 (all p < 0.05 apart from tiotropium).
Conclusions: Indacaterol provided clinically important improvements in dyspnoea and health
status that were at least as good as and often better than those observed with existing bronchodi-
lator treatments for COPD.
ª 2011 Elsevier Ltd. All rights reserved.) 208 725 5371; fax: þ44 (0) 208 725 5955.
(P.W. Jones).
1 Elsevier Ltd. All rights reserved.
Effect of indacaterol on clinical outcomes in COPD 893Introduction MethodsChronic obstructive pulmonary disease (COPD) is a progres-
sive and disabling disease. An accelerated decline in forced
expiratory volume in 1 s (FEV1) occurs alongside a decline in
patients’ ability to undertake physical activities and social
functioning, reflected in the measurement of clinical
outcomes including dyspnoea and health status. Dyspnoea
and health status are closely related,1 since a reduction in
dyspnoea may be expected to lessen the limitations on
daily activities and thus to improve health status. Regular
pharmacotherapy using long-acting inhaled bronchodilators
has been shown to provide improvements in dyspnoea and
health status, as well as in lung function (FEV1).
2e4
Indacaterol is a novel, inhaled, ultra-long-acting
b2-agonist bronchodilator recently approved in Europe for
the maintenance treatment of COPD.5 In large-scale regis-
tration studies, indacaterol provided 24-h bronchodilation
on once-daily dosing with an effect that was sustained
during treatment for up to 1 year.6e9 The relative effect of
indacaterol on trough FEV1 (measured 24 h following
dosing) after 12 weeks of treatment was reported to be
40e50 mL greater than the once-daily anticholinergic
bronchodilator, tiotropium,7 and 60e100 mL greater than
the trough FEV1 measured 12 h after dosing with the twice-
daily b2-agonists salmeterol and formoterol.
6,8 Though FEV1
is used as a global marker of COPD, it does not fully capture
the burden of COPD on patients.10
The aim of the present article is to assess the effect of
indacaterol on the important clinical outcomes of dysp-
noea and health status, by analysing pooled data from
three placebo-controlled studies. Both outcomes were
assessed using widely recognized methods that are vali-
dated for use in COPD: the baseline/transition dyspnoea
index (BDI/TDI)11 and the St George’s Respiratory Ques-
tionnaire (SGRQ).12 The studies had as active comparators
three inhaled long-acting bronchodilators currently avail-
able for COPD: the once-daily anticholinergic, tiotropium,
and the twice-daily b2-agonists, formoterol and salme-
terol. The pooled study data provide an opportunity to
evaluate the relative efficacy of the new and existing
bronchodilators.Table 1 Summary of study designs for the studies included in t
Study ID Design Num
NCT003934586 Phase III, randomized, double-blind,
double-dummy, placebo-controlled,
parallel-group, multicentre
173
eva
NCT004635677 Phase III, randomized, double-blind
(indacaterol and placebo) or open-label
(tiotropium), placebo-controlled,
parallel-group, multicentre
168
eva
NCT005679968 Phase III, randomized, double-blind,
double-dummy, placebo-controlled,
parallel-group, multicentre
100
eva
bid Z twice-daily; od Z once-daily.
a Data for this dose not included in this analysis.Patients
The three studies providing the pooled data had identical
entry criteria, recruiting male and female patients aged
40 years with a clinical diagnosis of moderate-to-severe
COPD13 and a smoking history of 20 pack-years. Post-
bronchodilator (salbutamol 400 mg) FEV1 was to be <80%
and 30% predicted and post-bronchodilator FEV1/forced
vital capacity <70%. Patients gave their written informed
consent before taking any study drug.
Study design
The study designs are summarized in Table 1 and are
reported in full elsewhere.6e8 Indacaterol was taken via
a single-dose dry-powder inhaler (DPI) (known as Onbrez
Breezhaler in Europe) and the active comparators were
taken via their proprietary DPIs. Other bronchodilators
were discontinued before the study, apart from salbutamol,
which patients could use as ‘rescue’ medication. Patients
taking inhaled corticosteroids (ICS) were allowed to
continue this as monotherapy (fixed combinations of ICS
and b2-agonists were replaced with the ICS alone) at
a stable dose and regimen during the studies. The study
protocols were approved by the respective institutional
review boards and ethics committees for the centres
concerned.
Objectives and outcomes
SGRQ total score and TDI total score were secondary effi-
cacy endpoints in all studies, the primary objective being to
test the superiority of the bronchodilator effect of inda-
caterol versus placebo (measured as ‘trough’ FEV1 after 12
weeks).
TDI total score
The BDI and TDI each have three domains: functional
impairment, magnitude of task andmagnitude of effort. Thehis overview.
ber of patients Treatments Treatment
duration
2 randomized; 1600
luable for efficacy
Indacaterol 300 mg od
Indacaterol 600 mg oda
Formoterol 12 mg bid
Placebo
52 weeks
3 randomized; 1665
luable for efficacy
Indacaterol 150 mg od
Indacaterol 300 mg od
Tiotropium 18 mg od
Placebo
26 weeks
2 randomized; 998
luable for efficacy
Indacaterol 150 mg od
Salmeterol 50 mg bid
Placebo
26 weeks
Table 2 Patient disposition (n, % of randomized) in the individual studies.
Study 16,a Study 27 Study 38
Randomized (total) 1304 (100) 1683 (100) 1002 (100)
Treated (total) 1303 (99.9) 1665 (98.9) 998 (99.6)
Discontinued (total) 348 (26.7) 392 (23.3) 164 (16.4)
Indacaterol 150 mg e 95 (22.6) 44 (13.2)
Indacaterol 300 mg 99 (22.7) 77 (18.4) e
Active comparator 112 (25.7) 89 (21.2) 50 (15.0)
Placebo 137 (31.7) 131 (30.8) 70 (20.9)
Discontinued for insufficient therapeutic effect
Indacaterol 150 mg e 4 (1.0) 1 (0.3)
Indacaterol 300 mg 12 (2.7) 9 (2.2) e
Active comparator 12 (2.8) 9 (2.1) 2 (0.6)
Placebo 30 (6.9) 17 (4.0) 15 (4.5)
Completed
Indacaterol 150 mg e 325 (77.4) 289 (86.8)
Indacaterol 300 mg 338 (77.3) 341 (81.6) e
Active comparator 323 (74.3) 331 (78.8) 284 (85.0)
Placebo 295 (68.3) 294 (69.2) 265 (79.1)
a 12-month data. Results from the indacaterol 600 mg treatment group (428 randomized patients) included in this study are not
presented here.
894 P.W. Jones et al.BDI domains are rated from 0 (severe) to 4 (unimpaired) and
summed to provide a BDI total score of from 0 to 12, with
a lower score indicating more severe dyspnoea. The TDI
domains are rated from3 (major deterioration) to 3 (major
improvement) and summed to give a total score from9 to 9.
Negative scores indicate deterioration, and a change from
BDI or difference between treatments of 1 point is regarded
as the minimum clinically important difference (MCID).14e16
Results are also presented for the proportion of patientsTable 3 Patient characteristics at baseline (pooled data set).
Indacaterol 150 mg Indacaterol 300 m
N 746 853
Age, years 63 (9.1) 64 (8.9)
Age 65 years, % 47 47
M/F, % 67/33 72/28
Race, %
Caucasian 81 89
Black 2 2
Asian 13 6
Other 4 3
BMI, kg/m2 27 (5.8) 27 (5.5)
FEV1, L
a 1.3 (0.48) 1.4 (0.46)
FEV1, L
b 1.5 (0.50) 1.5 (0.49)
FEV1, % pred.
b 55 (14.3) 55 (14.2)
ICS use, % 41 47
Ex-smoker/smoker, % 55/45 57/43
BDI total scorec 6.7 (2.3) 6.6 (2.2)
SGRQ total scorec 44.5 (18.9) 44.5 (17.9)
Data are mean (SD) unless otherwise stated.
a Pre-salbutamol.
b Post-salbutamol.
c Baseline data for patients evaluated at 6-month assessments.responding with a change from the baseline score of equal to
or greater than the MCID (‘responder analysis’).
Dyspnoea was measured at baseline using the BDI and
after 4, 8, 12 and either 24 or 26 weeks of treatment in the
individual studies (continuing to 44 and 52 weeks in the 1-
year study) using the TDI, which captures changes from
baseline. To permit comparisons across trials, data are
pooled here from the 24-week assessment (for the 1-year
study) and the 26-week assessment (for the two 6-monthg Formoterol Salmeterol Tiotropium Placebo
556 333 415 1185
64 (8.5) 63 (9.2) 64 (8.8) 64 (8.6)
49 47 48 47
75/25 75/25 65/35 73/27
92 78 84 85
1 0 2 1
2 16 12 10
5 7 2 4
27 (5.1) 26 (5.3) 27 (6.3) 26 (5.3)
1.3 (0.43) 1.4 (0.48) 1.3 (0.49) 1.3 (0.47)
1.5 (0.47) 1.5 (0.49) 1.5 (0.51) 1.5 (0.49)
53 (14.0) 53 (13.6) 54 (15.6) 54 (14.3)
50 46 35 44
59/41 54/46 55/45 57/43
6.5 (2.1) 6.7 (2.2) 6.6 (2.2) 6.6 (2.2)
44.0 (16.8) 43.1 (18.4) 44.5 (18.2) 43.9 (17.4)
3 Indacaterol 300 µg 
Formoterol 
1 
2 
Placebo 
MCID
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(where feasible), trained assessor, with the same assessor
completing all the BDI/TDI assessments for an individual
patient. BDI/TDI was assessed after the patients had
completed the SGRQ questionnaire.
SGRQ total score
The SGRQ contains 50 items covering three aspects, or
components, of health. The ‘symptoms’ component covers
respiratory symptoms, their frequency and severity. The
‘activity’ component covers activities that cause or are
limited by breathlessness. The ‘impacts’ component covers
various aspects concerned with social functioning and
psychological disturbances resulting from airways disease.
Individual component and total scores are calculated. The
total score is on a scale of 0e100. Higher values correspond
to greater impairment of quality of life, and a change of 4
units (compared with another treatment or with baseline) is
the MCID.17 The proportions of patients responding with
a change from baseline of equal to or greater than the MCID
are also presented.
SGRQ scores were measured at baseline and after 4, 8,
12 and 24 or 26 weeks of treatment in individual studies
(again continuing to 44 and 52 weeks in the 1-year study).
To permit comparisons across trials, data are pooled here
from the 24 and 26-week assessments. Existing validated
local-language versions of the questionnaires were used in
each participating country. Patients completed the ques-
tionnaires in a quiet area during clinic visits, and were to
complete the SGRQ before any other assessment in order to
avoid influencing their responses.3 Indacaterol 150 µg a 
il e s 
1 
2 
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Figure 1 Change from baseline in TDI total score in indi-
vidual studies (a),6 (b)7 and (c).8 Data are unadjusted
means  SE. Dotted line indicates the MCID (minimum clinically
important difference) from baseline.Statistical analysis
Outcomes were analysed using a mixed-model analysis of
covariance (ANCOVA) containing treatment as a fixed effect
with the baseline measurement (SGRQ or BDI total score)
and baseline FEV1 reversibility as covariates. To reflect the
randomization scheme the model included smoking status,
country and study as fixed effects and centre nested within
country as a random effect. For the responder analyses, the
proportions of patients who achieved the minimum clini-
cally important change from baseline were analysed using
a logistic regression model with the same covariates and
terms as the mixed-model ANCOVA. The estimated adjusted
treatment contrasts, as least squares mean (LSM) for the
scores and adjusted odds ratios for the responder analyses,
are presented along with the associated 95% confidence
intervals (CI) and two-sided p-values. Individual study data
summarizing changes in SGRQ and TDI total scores are also
presented. No adjustments for multiplicity were made.
If data were missing or insufficient for any one of the TDI
domains, a total score was not calculated. Missing total
scores were imputed using the last observation carried
forward (LOCF), but not by more than 11 weeks. Missing
items within the SGRQ questionnaire were handled
according to the user guide, in which a tolerable number of
missed items are allowed for each of the three component
scores (up to two from symptoms, four from activity and six
from impacts), and the total score is weighted accordingly.
Missing data for the SGRQ total score itself (i.e. missedassessments at a clinic visit) were imputed by LOCF,
provided the two visits were no more than 11 weeks apart
(baseline data were not carried forward).
The endpoints were analysed for the pooled COPD
6-month efficacy population, which comprised all inten-
tion-to-treat patients (all randomized patients who
received at least one dose of study drug) in the 6-month
electronic database for these studies.
Results
Patient disposition in the individual studies is shown in
Table 2. Patient demographic and clinical characteristics
for the pooled population are shown in Table 3. Most
patients had moderate (51e56% across the treatment
groups) or severe COPD (40e42%).
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Figure 2 Differences between active and placebo treat-
ments in TDI total score after 6 months (pooled data). Data are
least squares means and 95% CI. )))p < 0.001 vs placebo
(yp Z 0.011 vs formoterol). Patient numbers were 602 (inda-
caterol 150 mg), 651 (indacaterol 300 mg), 317 (formoterol), 320
(tiotropium), 279 (salmeterol) and 823 (placebo). Dotted line
indicates the MCID (minimum clinically important difference)
vs placebo.
896 P.W. Jones et al.Dyspnoea
Unadjusted mean TDI total scores for each treatment group
in the three individual studies are shown in Fig. 1. Adjusted
mean differences in TDI total score between active and
placebo treatment groups for the pooled data set at the
6-month assessment are shown in Fig. 2. All active treat-
ments achieved statistically significant increases in TDI
total score relative to placebo; the only statistically
significant difference between active treatments was that
between indacaterol 300 mg and formoterol. The mean
improvements relative to placebo with indacaterol 150 mg
and 300 mg (but not with the other three active treatments)
met or exceeded the threshold for the MCID. The numerical
difference between indacaterol 300 mg and 150 mg was not
statistically significant.Active (n/N)   Placebo  (n/N)
185/320
172/317
151/279
364/602
429/651
373/823
Odds ratio (9
Favours placebo
Inda
IndaFormoterol
Salmeterol
Tiotropium
0 1 2
Favours active 
Figure 3 Odds ratios relative to placebo for likelihood of achiev
(change of 1 point from baseline) after 6 months of treatment (p
yp < 0.05 vs salmeterol, zp < 0.001 vs tiotropium, xp < 0.05 vs indFig. 3 shows the odds ratios relative to placebo for the
likelihoodof patients achieving theMCID inTDI total score. The
odds ratioversusplacebowashighest for the indacaterol 300mg
treatment group, and this group also had statistically signifi-
cantodds ratios relative to salmeterol (1.50 [95%CI 1.01, 2.24];
p< 0.05), tiotropium (1.80 [95% CI 1.30, 2.48]; p< 0.001) and
indacaterol 150 mg (1.41 [95% CI 1.05, 1.88]; p < 0.05).
In the individual studies contributing to this analysis, the
use of salbutamol as rescue medication decreased (in
comparison with placebo) by an additional 1.0e1.1 puffs/
day with indacaterol 150 mg, 1.2e1.7 puffs/day with inda-
caterol 300 mg, 1.3 puffs/day with formoterol, 0.8 puffs/
day with salmeterol, and 0.6 puffs/day with tiotropium.6e8
Health status
Mean results from individual studies for the SGRQ total
score are shown in Fig. 4 as changes from baseline. All
treatment arms, including placebo, showed a decrease (i.e.
improvement); the changes with indacaterol 150 mg and
300 mg relative to baseline exceeded the MCID within 4
weeks in all studies and this benefit remained for the rest of
the study periods. In the pooled data set, differences in the
adjusted mean scores between active and placebo treat-
ments were largest in the indacaterol 150 mg treatment
group (Fig. 5). This treatment group was the only one to
exceed the MCID relative to placebo, and differed signifi-
cantly from the tiotropium treatment group.
The analysis of responding patients (Fig. 6) showed
significant odds ratios for all active treatments versus
placebo apart from tiotropium. The odds ratio relative to
placebo was highest for indacaterol 150 mg, and the odds
ratio for this group relative to tiotropium was also statis-
tically significant (1.51 [95% CI 1.12, 2.04]; p Z 0.007).
Safety and tolerability
Indacaterol was reported to be well tolerated and to have
a good safety profile in each of the studies; further details
can be found elsewhere.6e8Odds ratio (95% CI)
1.49 (1.10, 2.04)
2.02 (1.46, 2.80)
1.79 (1.26, 2.54)
1.91 (1.49, 2.45)
2.69 (2.11, 3.43)
*
***
**
***
***
§‡†
5% CI)
caterol 150 µg
caterol 300 µg
3 4
treatment
ing minimum clinically important difference in TDI total score
ooled data). )p < 0.05, ))p < 0.01, )))p < 0.001 vs placebo,
acaterol 150 mg.
Figure 4 Change from baseline in SGRQ total score in indi-
vidual studies (a),6 (b)7 and (c).8 Data are unadjusted
means  SE. Dotted line indicates the minimum clinically
important difference (MCID) from baseline.
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Figure 5 Differences between active and placebo treat-
ments in SGRQ total score after 6 months (pooled data). Dotted
line indicates the minimum clinically important difference
(MCID) from placebo. Data are least squares means and 95% CI.
)p < 0.05, )))p < 0.001 vs placebo; zp Z 0.003 vs tiotropium.
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As well as measuring the extent to which bronchodilator
treatment improves airflow, it is arguably more important
to know how therapy affects dyspnoea and health status.
Health status measurement allows quantification of the
effect of disease on daily life and well-being from
the patient’s viewpoint. This analysis allows us to examine
the effect of a new bronchodilator on these endpoints.
Dyspnoea and health status were both assessed using vali-
dated multidimensional instruments that are widely used to
measure treatment effects in COPD.18e21 There was
a consistent effect of indacaterol in all three studies
reviewed here, with 6-month improvements from baseline
of 2.3 to 2.7 in TDI total score and from 6 to 7 in SGRQ
total score (unadjusted).
Pooling data from several studies of identical or similar
design and inclusion criteria allowed the comparison of theeffects of all the currently available long-acting bronchodi-
lators for COPD. Tiotropium was administered open-label,
because blinded tiotropium was not available to the study
sponsors, while indacaterol, the twice-daily b2-agonists and
placebo were administered double-blind. The possible effect
of bias from this aspect of the study design has been
acknowledged elsewhere.7 A meta-analysis of blinded tio-
tropiumstudiesbyBarretal.4 reportedaneffectof tiotropium
onSGRQtotal scoreof3.3 versusplaceboandanoverall odds
ratio for response of 1.92 (although with some heterogeneity
among studies). That is a greater improvement than shown in
this analysis, but the percentage of patients who exceeded
the MCID in this analysis (48%) is almost identical to that
reported in the meta-analysis and by individual studies using
blinded tiotropium (49%).4,22,23 For TDI total score, the
authors of the meta-analysis reported that data were inade-
quate to calculate a mean difference for tiotropium versus
either salmeterol or placebo.4 However, individual studies
report an effect on TDI total score of approximately one point
versus placebo,22,24 similar to that in the present pooled
analysis. Again, it is possible that the lack of blinding of tio-
tropium may have influenced the self-assessed SGRQ scores,
but responder rates were identical to those previously
reported.4,22,23 Set against the previously obtained data with
tiotropium, the effect of indacaterol was very similar (150 mg)
or superior (300 mg) for TDI total score, and similar (300 mg) or
a little better (150 mg) for SGRQ total score.
The comparisons of indacaterol with the twice-daily b2-
agonists were fully blinded. For TDI total score, the broad
finding was that the 150 mg dose of indacaterol had similar
effects to the twice-daily b2-agonists, while the 300 mg dose
was superior. For SGRQ total score, indacaterol 300 mg had
similar effects to those of formoterol and salmeterol, while
the 150 mg dose was numerically better. Indacaterol had
a significantly better effect than salmeterol in terms of TDI
responder rates, even though in the present pooled data set
salmeterol had a larger effect on TDI total score and SGRQ
total score than in some,24e28 but not all, previous
studies.29,30
In terms of difference between the two doses, the 300 mg
dose of indacaterol was the only evaluated treatment to
165/345
196/385
139/284
345/620
362/671
358/862
0.5 1 1.5 2 2.5 3
1.29 (0.97, 1.72)
1.54 (1.17, 2.03)
1.82 (1.31, 2.53)
1.95 (1.54, 2.46)
1.63 (1.30, 2.05)
**
***
***
‡
***
Active (n/N)   Placebo  (n/N) Odds ratio (95% CI)Odds ratio (95% CI)
Indacaterol 150 µg
Indacaterol 300 µgFormoterol
Salmeterol
Tiotropium
Favours placebo Favours active treatment
Figure 6 Odds ratios relative to placebo for likelihood of achieving minimum clinically important difference in SGRQ total score
(improvement of 4 units from baseline) after 6 months of treatment (pooled data). ))p < 0.01, )))p < 0.001 vs placebo,
zp Z 0.007 vs tiotropium.
898 P.W. Jones et al.achieve a mean TDI score above the MCID. This dose also
showed a numerically superior mean benefit compared with
150 mg, but this difference was not significant. At an indi-
vidual patient level, however, there was a significantly
higher odds ratio for a clinically important TDI response with
the 300 mg dose compared with 150 mg. Dyspnoea is the main
reason why patients initially present with COPD,18 so this is
an important finding for a new treatment, since dyspnoea is
a disabling and frightening symptom for COPD patients, the
more so as the disease progresses.31e33 The 300 mg dose may
therefore provide a useful progression from the starting dose
of 150 mg once-daily. A recent report of a 1-year study
showed that a higher dose of 600 mg once-daily did not
further improve efficacy beyond that provided by a dose of
300 mg once-daily.6
The effect of indacaterol on dyspnoea was reflected in
a reduction in the patients’ need for salbutamol as rescue
medication in the individual studies contributing to this
analysis.6e8
The number of patientswho completed the studies and the
reasons for early discontinuation were reasonably consistent
across treatment groups. The overall completion rate for
patients randomized to placebo in the individual studies was
lower than for patients in the active interventions,6e8 with
a greater proportion of patients withdrawing from placebo
groups (versus the active treatments) owing to unsatisfactory
therapeutic effect. Missing assessmentswere dealt with using
LOCF. If the patients receiving placebo discontinued because
of deteriorating symptoms, an observation reported in other
studies,34,35 the use of LOCF would be conservative, since
a higher value would be carried forward than would be
observed if the patients remained in the study. For the first
two of the three studies evaluated here,6,7 two additional
confirmatory analyses were undertaken in order to test the
robustness of the LOCF analyses for the SGRQ and TDI total
scores e first without LOCF, and second using a repeated-
measures approach. Both sets of analyses were consistent
with the LOCF models previously presented [results not
shown].
In conclusion, the present results demonstrate the
benefits in patient-related outcomes that may be obtainedwith the use of indacaterol and underline the rationale for
its use as an initial maintenance therapy for patients with
COPD. Indacaterol provides clinically important benefits
and will be a useful alternative to existing agents.
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